Skip to main content
Premium Trial:

Request an Annual Quote

Toronto Stock Exchange Resumes Trading of Fund Active in Genomics

NEW YORK, Dec. 19 - The Toronto Stock Exchange has resumed trading of the Health Care and Biotechnology Venture Fund at 1:15 p.m. EST, the organization said on Wednesday afternoon.

 

Trading in the well-known fund, which invests heavily in the genomics sector, were suspended at 11:48 a.m. EST and investors and reporters were told to await a press release. None was issued and it remains unclear what triggered the suspension.

 

Representatives of MDS Capital did not return telephone calls seeking comment.

 

The Health Care and Biotechnology Venture Fund is a closed-end investment trust founded in 1992 to invest in the health care and biotechnology sectors with "high growth potential," according the its website.  It has invested close to $4 million in a wide range of firms in the genomics sector, including DoubleTwist, MDS Proteomics, and Ciphergen Biosystems.

 

The fund boasts a total investment portfolio valued at $30 million. It comprises seven privately held firms and 13 publicly traded companies in sectors spanning pharmaceuticals, biotechnology, medical equipment and devices, and health-care delivery. Nine of these companies are located in the US and 11 are based in Canada.

 

MDS Capital Corp. holds an 11.7 percent stake in the fund.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.